Key Takeaways
- •Influenza A HA 116-131 (YDVPDYASLRSLVASS): An extended 16-mer CD4+ epitope containing the core YDVPDYASL sequence within the HA1 region. Validated for broad binding across HLA-DRB101:01, HLA-DRB104:01, and HLA-DRB1*07:01.
- •Influenza A HA 271-286 (RGYFKMRTGKSSIMRS): A broadly recognized 16-mer CD4+ helper epitope used for population-wide immunomonitoring across diverse HLA Class II alleles (HLA-DR1, DR10, DQ6).
- •Influenza A HA 306-318 (PKYVKQNTLKLAT, also annotated as HA 322-334 when including the 16-aa signal peptide): One of the most widely cited helper T-cell epitopes from HA1. It demonstrates exceptional promiscuous binding across HLA-DRB101:01, DRB104:01, DRB107:01, DRB111:01, and DRB5*01:01, among others.
- •Influenza A HA 322-333 (PKYVKQNTLKLA): A key 12-mer linear CD4+ epitope derived from the HA1 subunit (H3N2 A/Aichi/2/1968). It is specifically restricted to HLA-DRA01:01 / DRB101:01 for targeted recall assays.
- •Influenza B HA 322-334 (PYYTGEHAKAIGN): An essential HA-derived reference target for mapping lineage-specific CD4+ T-cell responses against Influenza B. It enables accurate lineage cross-reactivity profiling alongside Influenza A HA panels.
Why Influenza HA Is a Benchmark for Peptide Clinical Trial Work
Influenza A and B Hemagglutinins (HA) are best known as the primary targets for neutralizing antibodies. Less discussed is their role as a critical driver of CD4+ helper T-cell responses. CD4+ T cells directed against HA provide the B-cell help needed for durable antibody generation and mediate cross-reactive protection against emerging seasonal strains.
For immunologists, HA is an unusual target. Its sequence contains both highly variable antigenic sites and immunodominant, promiscuous CD4+ epitopes. Targets like HA 306-318 (HA 322-334) bind broadly across multiple HLA-DR alleles. That breadth makes them indispensable positive controls for evaluating recall responses, mapping TCR kinetics, and benchmarking universal flu vaccine candidates.
!Influenza A virus protein structure
Precise Peptide Tools Form the Foundation of Immunomonitoring
Any peptide clinical trial or translational immunology program depends on reagent quality. Overlapping peptide pools allow broad epitope screening. Single epitopes are necessary for deconvoluting specific HLA-restricted responses. Without both, a study cannot separate a genuine T-cell response from background noise or cross-reactivity.
For human immunomonitoring and preclinical model evaluations, HA-derived reagents are typically categorized by host restriction. This matters because HLA restriction determines which donors or animal models will respond, and therefore which endpoints are measurable.
If you are planning a study that uses these reagents, the Peptide Reconstitution Calculator and Peptide Stability Calculator help you prepare and store epitope panels consistently across cohorts.
Human MHC Class II / CD4+ Epitopes in Influenza HA
A complete H1N1 Hemagglutinin peptide pool provides full sequence coverage for CD4+ and CD8+ T-cell immunomonitoring, epitope mapping, and cross-strain vaccine research. Within that pool, several single epitopes serve as reference standards.
- Influenza A HA 116-131 (YDVPDYASLRSLVASS): An extended 16-mer CD4+ epitope containing the core YDVPDYASL sequence within the HA1 region. Validated for broad binding across HLA-DRB101:01, HLA-DRB104:01, and HLA-DRB1*07:01.
- Influenza A HA 271-286 (RGYFKMRTGKSSIMRS): A broadly recognized 16-mer CD4+ helper epitope used for population-wide immunomonitoring across diverse HLA Class II alleles (HLA-DR1, DR10, DQ6).
- Influenza A HA 306-318 (PKYVKQNTLKLAT, also annotated as HA 322-334 when including the 16-aa signal peptide): One of the most widely cited helper T-cell epitopes from HA1. It demonstrates exceptional promiscuous binding across HLA-DRB101:01, DRB104:01, DRB107:01, DRB111:01, and DRB5*01:01, among others.
- Influenza A HA 322-333 (PKYVKQNTLKLA): A key 12-mer linear CD4+ epitope derived from the HA1 subunit (H3N2 A/Aichi/2/1968). It is specifically restricted to HLA-DRA01:01 / DRB101:01 for targeted recall assays.
- Influenza B HA 322-334 (PYYTGEHAKAIGN): An essential HA-derived reference target for mapping lineage-specific CD4+ T-cell responses against Influenza B. It enables accurate lineage cross-reactivity profiling alongside Influenza A HA panels.
!MHC class I and class II presentation pathways
The HA 306-318 epitope deserves particular attention. Its promiscuous binding profile means a single reagent can serve as a positive control across genetically diverse donor populations. That reduces the number of control arms needed in a peptide clinical trial and improves comparability between sites.
Murine MHC-Restricted Epitopes for Preclinical Models
Preclinical work often requires murine-restricted epitopes to bridge findings toward human translation. Three commonly used H-2-restricted HA epitopes are:
- Influenza A HA 332-340 (H-2Db)
- Influenza A HA 462-470 (H-2Kd)
- Influenza A HA 533-541 (H-2Kd)
!Murine model for preclinical peptide research
These reagents allow researchers to track epitope-specific T-cell expansion in defined genetic backgrounds. When paired with the human HLA Class II panel above, they support a translational arc from mouse immunogenicity to human recall response.
Matrix Protein 1: The Structural Backbone of Influenza
Matrix Protein 1 (M1) is the most abundant viral protein. It coordinates every stage of the replication cycle, from viral entry and uncoating to nuclear transport and budding. Its domain architecture, structural shifts, and essential roles in the viral life cycle make it a complementary target to HA in influenza research programs.
!Influenza Matrix Protein 1 structure
For teams building a peptide clinical trial around influenza immunity, HA and M1 together cover both the antibody-facing surface and the internal structural machinery. That combination supports broader immune profiling than either target alone.
How to Validate Peptide Reagents Before a Clinical Trial
A peptide clinical trial is only as reliable as the reagents that feed it. Before committing an epitope panel to a regulated study, confirm the following:
- Sequence identity. Verify the exact amino acid sequence against the published reference, including signal peptide annotations. HA 306-318 and HA 322-334 refer to the same core epitope with different numbering conventions.
- HLA restriction data. Confirm which alleles the epitope binds. Promiscuous binders like HA 306-318 are useful across populations; restricted binders like HA 322-333 are useful for targeted recall assays.
- Purity and counterion content. Use the Purity Analyzer to review certificate of analysis data before accepting a lot.
- Solubility in your assay buffer. Run the Solubility Predictor to avoid failed reconstitutions mid-study.
- Stability across the study window. The Stability Calculator helps set storage and handling limits.
!HLA peptide binding and T-cell recognition
These checks are not bureaucratic. A single mis-sequenced or degraded epitope can produce false negatives that look like non-responsiveness in a donor cohort.
Reading Peptide Clinical Trial Evidence Critically
When you encounter a claim that a peptide is "validated" for T-cell work, ask what validation means. In the HA literature, validation typically refers to documented binding across specific HLA alleles, not to clinical efficacy. HA 116-131, HA 271-286, and HA 306-318 each carry defined allele lists. That is the level of specificity a peptide clinical trial protocol should demand.
Equally important is understanding what these reagents are for. They are tools for immunomonitoring, epitope mapping, and benchmarking vaccine candidates. They are not themselves therapeutics. Keeping that distinction clear prevents overreach when translating preclinical data into trial design.
For a broader grounding in compound terminology, the Peptide Glossary covers the vocabulary used across epitope and immunogenicity research. Researchers comparing related compounds may also find the TB-500 Research Guide and BPC-157 Research Guide useful for understanding how peptide characterization standards differ across research areas.
Key Takeaway
Influenza HA research shows what a well-characterized peptide panel looks like: defined sequences, documented HLA restriction, and clear roles for each reagent. Applying that same standard to any peptide clinical trial, and verifying purity, solubility, and stability before use, is what separates reproducible immunomonitoring from inconclusive data. Start by reviewing available compounds in the Volta Peptides catalog and confirm handling parameters with our free peptide tools.
Related Research Compounds
Looking for high-purity research peptides? Browse our catalog for HPLC-verified compounds.
| Compound | Purity | Size | Price |
|---|---|---|---|
| TB-500 5mg | ≥98% | 5mg | $29.00 |
| BPC-157 5mg | ≥98% | 5mg | $34.00 |
| BPC-157 10mg | ≥98% | 10mg | $44.00 |
Frequently Asked Questions
Q: What does peptide clinical trial mean in peptide research?
A: In peptide research, a peptide clinical trial refers to a study in which peptides are used either as the intervention or as reagents that measure immune response. In influenza HA work, peptides like HA 306-318 function as positive controls and epitope-mapping tools rather than as therapeutics. The term covers both uses, which is why precise sequence and HLA restriction data matter.
Q: Which Volta resources help verify peptide clinical trial reagents?
A: Volta's Purity Analyzer supports certificate of analysis review. The Solubility Predictor and Stability Calculator help confirm assay compatibility and storage limits. The Peptide Glossary clarifies terminology used across epitope research.
Q: Why is HA 306-318 considered a promiscuous CD4+ epitope?
A: HA 306-318 (PKYVKQNTLKLAT), also annotated as HA 322-334, demonstrates broad binding across HLA-DRB101:01, DRB104:01, DRB107:01, DRB111:01, and DRB5*01:01, among others. That breadth allows it to serve as a positive control across genetically diverse donor populations.
Q: What is the difference between HA 306-318 and HA 322-334?
A: They refer to the same core epitope with different numbering. HA 322-334 includes the 16-amino-acid signal peptide in the count, while HA 306-318 does not. Researchers should confirm which convention a reagent certificate uses before comparing datasets.
Q: Are murine HA epitopes necessary for peptide clinical trial preparation?
A: They are commonly used to bridge preclinical and human data. Influenza A HA 332-340 (H-2Db), HA 462-470 (H-2Kd), and HA 533-541 (H-2Kd) allow epitope-specific T-cell tracking in defined genetic backgrounds before human HLA-restricted panels are applied.
